多发性骨髓瘤及少见浆细胞疾病的规范化诊断、预后评价及整体治疗，复发难治性患者的个体化诊疗；自体造血干细胞移植治疗；恶性淋巴瘤的规范化诊治。

发表多篇多发性骨髓瘤相关SCI论文，分别发表在Molecular Cancer Research、Leukemia & Lymphoma、Hematology等杂志、参与编译《威廉姆斯血液学手册第9册》、参与多项国家自然科学基金研究项目。

1.Chenxing Du, Lingna Li, Lugui Qiu, Gang An, et al. The age-dependent changes in risk weights of the prognostic factors for multiple myeloma, Hematology, 2023, 28(1): 1-9.

2.Chenxing Du, Xuehan Mao, Lugui Qiu, Gang An, et al. 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib, Leukemia & Lymphoma, 2019, 12(12): 1-10.

3.Tengteng Yu, Chenxing Du, Xiaoke Ma, Mu Hao, et al. Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a, MolecularCancer Research, 2020, 18(7): 1063-1073.

4.Chenxing Du, Lugui Qiu. 1q21 Gain May Challenge the Role of t(4;14) As an Adverse Prognostic Marker of Multiple Myeloma. 61th 美国血液学年会 摘要成就奖, #4343.

5.Zhongqing Li, Lanting Liu, Chenxing Du et al. Therapeutic effects of oligo-single-stranded DNA mimicking of hsa-miR-15a-5p on multiple myeloma, Cancer Gene Ther. 2020, 27(12):869-877.

6.杜辰星, 李增军, 邱录贵. 多发性骨髓瘤的预后与分层策略, 国际输血及血液学杂志, 2017, 40(2): 113-119.

中国抗癌协会血液肿瘤专业委员会会员、血液肿瘤整合康复专业委员会会员。